Safety and efficacy of a combination therapy with Revlimid, Adriamycin and dexamethasone (RAD) in relapsed/refractory multiple myeloma (MM): A single-centre experience

Annals of Hematology

Volumn 90, Issue 1, 2011, Pages 115-116

  Caravita, Tommaso ^a   Siniscalchi, Agostina ^a   Tendas, Andrea ^a   Cupelli, Luca ^a   Ales, Micaela ^a   Perrotti, Alessio ^a   Niscola, Pasquale ^a   De Fabritiis, Paolo ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DEXAMETHASONE; DOXORUBICIN; HEMOGLOBIN; LENALIDOMIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; AUTOLOGOUS STEM CELL TRANSPLANTATION; BOLUS INJECTION; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CAUSE OF DEATH; CELL INFILTRATION; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; LETTER; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROLOGIC DISEASE; PLASMA CELL; PNEUMONIA; PRIORITY JOURNAL; SALVAGE THERAPY; SINGLE DRUG DOSE; THROMBOCYTOPENIA; THROMBOSIS; THROMBOSIS PREVENTION;

EID: 85027953583     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-010-0967-4     Document Type: Letter

References (8)

1. Patriarca F, Petrucci MT, Bringhen S, Baldini L, Caravita T, Corradini P, Corso A, Di Raimondo F, Falcone A, Ferrara F, Morabito F, Musto P, Offidani M, Petrini M, Rizzi R, Semenzato G, Tosi P, Vacca A, Cavo M, Boccadoro M, Palombo A (2009) Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts. Eur J Haematol 82:93-105
2. SK Kumar SV Rajkumar A Dispenzieri, et al. 2008 Improved survival in multiple myeloma and the impact of novel therapies Blood 111 2516 2520 1:CAS:528:DC%2BD1cXivFaktrk%3D 10.1182/blood-2007-10-116129 17975015
3. JL Harousseau 2008 New treatments in multiple myeloma: beyond optimal treatment Ann Oncol 19 5 68 70 10.1093/annonc/mdn314
4. Baz R, Walker E, Karam MA et al (2006) Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol 17:1766-1771
5. GJ Morgan SA Schey P Wu, et al. 2007 Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients Br J Haematol 137 268 269 10.1111/j.1365-2141.2007.06538.x 17408469 (Pubitemid 46537629)
6. Richardson PG, Jagannath S, Avigan DE et al (2006) Lenalidomide plus bortezomib (Rev-Vel) in relapsed and/or refractory multiple myeloma (MM): final results of a multicenter phase I trial [abstract]. Blood 108:124a. Abstract no. 405
7. S Knop C Gerecke P Liebisch MS Topp U Platzbecker O Sezer C Vollmuth K Falk A Glasmacher U Maeder H Einsele RC Bargou 2009 Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom) Blood 113 4137 4143 1:CAS:528: DC%2BD1MXlvVGis7k%3D 10.1182/blood-2008-10-184135 19182205
8. BGM Durie JL Harousseau J San Miguel, et al. 2006 International uniform response criteria for multiple myeloma Leukemia 20 1467 1473 1:STN:280:DC%2BD28rgt1aqtA%3D%3D 10.1038/sj.leu.2404284 16855634 (Pubitemid 44264086)